Duloxetine
Product Images NDC 57237-019

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 57237-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A line graph comparing the proportion of patients experiencing relapse over time between Duloxetine and placebo groups. The x-axis represents time in days from randomization to relapse, and the y-axis shows the proportion of patients with relapse. Two lines are plotted: a solid line for Duloxetine and a dashed line for placebo.*

FDA Label Image

Package Label-principal Display Panel (20 mg (60 Capsules Bottle))

Label for Duloxetine Delayed-Release Capsules USP 20 mg, containing 60 capsules. The label includes dosing and storage instructions, pharmacist dispensing guidance, and warnings about the bottle seal. Distributed by Rising Health, LLC, made in India. Features a barcode and NDC 57237-017-60.*

FDA Label Image

Package Label-principal Display Panel (30 mg (30 Capsules Bottle))

Label for Duloxetine Delayed-Release Capsules USP 30 mg by Rising Pharma Holdings, Inc. The carton indicates a dosage strength of 30 mg with 30 capsules per container. It includes storage instructions, a pharmacist dispensing note, manufacturing information stating "Made in India," and barcodes for product identification.*

FDA Label Image

Package Label-principal Display Panel (60 mg (30 Capsules Bottle))

Label of Duloxetine Delayed-Release Capsules USP 60 mg by Rising Pharma Holdings, Inc. The label specifies 30 capsules per package, delayed-release form, with a NDC code 57237-019-30. It includes storage instructions, a dosage note directing users to accompanying literature, and warnings about container seal integrity. Distributed by Rising Health, LLC, made in India.*

FDA Label Image

Figure-2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time (days) between Duloxetine treatment and placebo. The x-axis represents the time from randomization to relapse in days, ranging from 0 to 300, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. Duloxetine is represented by a solid line and placebo by a dashed line, demonstrating lower relapse proportions with Duloxetine.*

FDA Label Image

Figure-3 (Duloxetine Fig3)

A line graph illustrating the percentage of patients improved by various levels of percent improvement in pain from baseline. Four groups are plotted: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The y-axis shows the percentage of patients improved, and the x-axis shows the percent improvement in pain, ranging from 0 to 100.*

FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)

This line graph depicts the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The data show trends of patient improvement with varying pain reduction percentages on the x-axis and corresponding improvement percentages on the y-axis.*

FDA Label Image

Figure 5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Data compare effectiveness of Duloxetine dosages to placebo over increasing pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine Fig6)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The x-axis shows percent improvement in pain in increments from greater than 0 to 100, and the y-axis shows percent of patients improved from 0 to 100 percent. Vertical lines highlight thresholds at >30 and >50 percent improvement.*

FDA Label Image

Figure 7 (Duloxetine Fig7)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline. It includes two data series: placebo (marked with X) and Duloxetine 60/120 mg once daily (marked with diamonds). The graph shows trends in patient improvement over a range of pain improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine Fig8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) comparing Duloxetine 60 mg once daily and placebo. The graph plots two curves that decline from left to right, illustrating higher percentages of patient improvement with Duloxetine across increasing pain improvement thresholds.*

FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine at 60/120 mg once daily versus placebo, illustrating patient response rates across different pain improvement thresholds.*

FDA Label Image

Chemical Structure (Duloxetine Str)

Chemical structure of Duloxetine, showing its molecular framework including a naphthalene group, a thiophene ring, and an amine with a hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.